Last reviewed · How we verify
Gycoren (prethcamide)
Gycoren (generic name: prethcamide) is a prethcamide drug. It is currently in unknown development.
Gycoren works by interacting with a specific molecular target to produce a therapeutic effect.
Gycoren is a small molecule modality composed of two related drugs, cropropamide and crotethamide. It is a respiratory stimulant sold under the brand name Micoren, which was developed by Ciba-Geigy.
At a glance
| Generic name | prethcamide |
|---|---|
| Drug class | prethcamide |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Imagine your body's cells have locks on them, and Gycoren has a key that fits into those locks. When it binds to the lock, it triggers a response that helps to treat a particular condition. This is a simplified explanation of how Gycoren works at a molecular level.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gycoren CI brief — competitive landscape report
- Gycoren updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Gycoren
What is Gycoren?
How does Gycoren work?
What is the generic name of Gycoren?
What drug class is Gycoren in?
What development phase is Gycoren in?
Related
- Drug class: All prethcamide drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing